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Study objective: To summarize and evaluate the available data describing the recovery parameters of
xenon anesthesia.
Design: Systematic review and meta-analysis.
Setting: Anesthesia for elective surgeries.
Patients: Systematic review of randomized controlled trials (RCTs) from databases including Medline
(1964-2013), the Cochrane Central Register of Controlled Trials (CENTRAL, 1990-2012), and Google
Scholar (1966-2013).
Interventions: Inhalation of xenon or other anesthetics was administered in elective surgery.
Measurements: Recovery parameters (time to recovery, alertness/sedation scale scores at “eye
opening,” bispectral index at “reaction on demand,” time to extubation, and time to orientation).
Main results: Eleven RCTs (N = 661 patients) met the inclusion criteria. Recovery from xenon
anesthesia was significantly faster in terms of the time to eye opening (mean difference [MD], −4.18
minutes; 95% confidence interval [CI], −5.03 to −3.32 minutes; P b .00001), the time to reaction on
demand (MD, −5.35 minutes; 95% CI, −6.59 to −4.11 minutes; P b .00001), the time to extubation
(MD, −4.49 minutes; 95% CI, −5.40 to −3.58 minutes; P b .00001), and the time to orientation
(MD, −4.99 minutes; 95% CI, −6.45 to −3.52 minutes; P b .00001).
Conclusions: This meta-analysis confirmed that recovery from xenon anesthesia is faster than other
inhalation anesthesia.
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66 B. Hou et al.1. IntroductionAn ideal anesthetic agent provides a rapid onset of effect
with a short time to recovery [1]. Xenon, an inert gas, has
attracted renewed interest because it possesses many of the
properties of an ideal inhaled anesthetic [1–3]. It is odorless,
nonpungent, nontoxic, nonexplosive, and nonflammable.
The blood-gas partition coefficient of an inhaled anesthetic
indicates its onset time and recovery speed. In the late 1990s,
Goto et al [4] confirmed that the blood-gas coefficient of xenon
may be lower than 0.14 and closer to 0.115, the lowest of all
known anesthetics. On the basis of xenon's pharmacokinetic
characteristics, it may have a profile that favors rapid recovery
from anesthesia. This offers a number of advantages. Results
from preclinical studies indicate the inhalational anesthetics
like xenon may increase neuronal apoptosis and reduce
neurogenesis and therefore affect neuron development in
neonatal animals. This may be of particular importance in
elderly patients. Elderly patients who undergo surgery have a
higher risk of experiencing postsurgery cognitive decline. TheFig. 1 Flow diagram of screening procmechanism is unclear, but nonclinical models suggest that
interactions between inhalational anesthetics and neurodegen-
erative mechanisms, similar to observed in Alzheimer disease,
may be responsible for postoperative cognitive dysfunction
[5]. Thus, inhalational anesthetics that have a rapid onset of
action and short recovery time may be preferable in certain
patient populations because these agents minimize the amount
time of patients under anesthesia.
To demonstrate the recovery advantages of xenon, we
performed a systematic review to quantitatively evaluate the
available evidence for the recovery parameters of xenon
versus other inhaled anesthetic agents.2. Methods
This systematic review and meta-analysis was conducted
according to the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines [6]. We
conducted a comprehensive literature search of MEDLINEess for studies eligible for analysis.
Table 1 Characteristics of the randomized trials included in the meta-analysis.
Study Age, y Sex
(male/female)
BMI ASA Type of anesthesia Anethesia
time, min
No. Type of surgery
Stoppe
et al [18]
20-80 6/34 25 ± 6 I-III Xenon (53-56 vol% MAC) 126 ± 46 20 Gynecology
Urology20-80 Sevoflurane
(1-1.4 vol% MAC)
126 ± 46 20
Cremer
et al [17]
65-75 24/15 – I-III Xenon (1.1-1.4 vol%
MAC in 30% oxygen)
121-181 18 Trauma
Orthopedics
ENT
Gynecology
Urology
Neurosurgery
Abdominal surgery
65-75 Sevoflurane (60 ± 3 vol%
MAC in 30% oxygen)
121-206 20
Fahlenkamp
et al [15]
22-74 27/30 – I-II Xenon (60 ± 5 vol%
MAC in 30% oxygen)
123 ± 9.6 29 Abdominal surgery
22-71 Sevoflurane (2 ± 0.2 vol%
MAC in 30% oxygen)
157 ± 13.7 28
Fahlenkamp
et al [14]
69 ± 1 23/16 – I-III Xenon (53.2 ± 0.8 vol%
MAC in 30% oxygen)
162 ± 19 19 Elective noncardiac surgery
70 ± 1 Sevoflurane (1.6 ± 0.1
vol% MAC in 30% oxygen)
148 ± 14 20
Bronco
et al [13]
59 ± 13 21/38 26 ± 4 I-II Xenon (60 vol% MAC) 133 ± 65 29 General surgery
Ear nose and throat surgery
Gynecological surgery
Orthopedic surgery and
urological surgery
58 ± 16 24 ± 5 Sevoflurane
(1.4 vol% MAC )
162 ± 76 30
Abranmo
et al [12]
23-49 14/6 42-83 I-III Xenon (60-65 vol% MAC) – 10 Roux-en-Y laparoscopic
gastric bypass19-57 39-71 Sevoflurane (1 vol% MAC) – 10
Stuttmann
et al [16]
41.5 14/47 – I-II Xenon (63 vol% MAC
in 30% oxygen)
– 31 Visceral strumectomy
Knee arthroscopy
Liposuction
Mammaplasty
38.9 – Isoflurane (0.6 vol%
MAC in 30% oxygen)
– 30
Coburn
et al [11]
65-75 24/14 – I-III Xenon (60 vol% MAC
in 30% oxygen)
98-138 18 Trauma
Head, neck, and ear
Gynecology
Urology
65-75 – Desflurane (5.2-5.5 vol%
MAC in 30% oxygen)
102-150 20
Rossaint
et al [3]
52.3 ± 16.7 113/111 – I-III Xenon (60 ± 5 vol%
MAC in oxygen)
175.3 ± 94.0 112 Elective surgery
52.5 ± 15.5 – Isoflurane-N2O (0.5 vol%
MAC isoflurane with
60 ± 5% N2O in oxygen)
180.1 ± 84.4 112
Goto et al [9] 33-58 7/47 – I-II Xenon (60 vol% MAC) 58-380 18 Elective lower
abdominal surgery32-64 – N2O-sevoflurane
(0.7 vol% MAC
sevoflurane with 60% N2O)
58-303 18
34-56 – N2O-isoflurane
(0.5 vol% MAC
isoflurane with 60% N2O)
61-296 18
Goto et al [2] 44 ± 3 –/– – I-II Xenon (60 vol% MAC) 122 ± 39 10 Elective total
abdominal hysterectomy44 ± 7 – N2O-sevoflurane
(0.7 vol% MAC
sevoflurane with 60% N2O)
119 ± 41 10
43 ± 4 – N2O-isoflurane
(0.5 vol% MAC
isoflurane with 60% N2O)
121 ± 26 10
67
Fig. 2 Methodological qualities of the included studies were
determined using the Cochrane Risk of Bias Assessment Tool. There
are 5 domains: sequence generation, allocation concealment,
blinding, incomplete outcome data, and selective outcome reporting.
68 B. Hou et al.(1964-2013), Cochrane Central Register of Controlled Trials
(CENTRAL, 1990-2012), and Google Scholar (1966-2013)
databases using the following search terms: xenon, methyl
ethers, sevoflurane, isoflurane, desflurane, enflurane, ha-
lothane, nitric oxide, mononitrogen monoxide, nitrogen
monoxide, endogenous nitrate vasodilator, and combina-
tions of these keywords. The search was limited to clinical
trials and randomized controlled trials (RCTs) in humans,
without any language restrictions. This initial search yielded
287 randomized clinical trials. We excluded children or
infant studies, case reports, and reviews by reading abstracts. All
RCTs included in the reviewhad 10 ormore patients; studieswith
less patients were excluded [7]. Bibliographies were checked for
retrieved articles. When the full text for an article could not be
found, authors were contacted to obtain a copy of the original.
Two authors (FJL and SPZ) independently screened all
articles and abstracts and assessed their methodological
validity using the Cochrane Risk of Bias Assessment Tool
[8]. Criteria that used for assessing the risk of bias included the
following: adequate sequence generation, allocation conceal-
ment, blinding, incomplete outcome data addressed, and free
of selective reporting. The decision on the suitability of a studyof our analysis was determined by 2 authors (SSO and LKY).
Disagreements on inclusion of the articles were resolved by
discussion among the evaluators. If an agreement could not be
reached between the 2 investigators, the decision was made by
a third investigator (SPZ).
The data were extracted independently by at least 2
individuals on a standardized data collection sheet. Mean-
while, data were extrapolated from available figures if the
data were not in the tables or the authors did not respond.
Dichotomous data on the presence or absence of adverse
effects were extracted and converted to incidence while
continuous data were recorded using mean and SD. Data
presented only as median and range were converted to mean
and SD using previously described methodology [9]. When
data were presented with 95% confidence intervals (CIs), the
SD was calculated from a standard formula for a normal
distribution (SD = 95% CI/1.96 × √n). Time data presented
in seconds were converted to total minutes by dividing the
time reported by 60. Collected data included baseline
characteristics of studies and recovery parameters (time to
“open eyes,” “reaction on demand,” “extubation,” and
“orientation”). These end points were chosen because of
their clinical importance and frequency of reporting. Two
studies [2,3] recorded the time point at which the patient
could count backward or count down from 10 to 1 instead of
the time point when the patient could react on demand.
2.1. Meta-analysis
All data extracted from the relevant studies were
transcribed to RevMan 5.0 (Review Manager, Cochrane
Collaboration, UK) for analysis. Studies with the same first
author were numbered [author et al (number)]. Studies of the
same first author with more than one intervention group were
numbered [author et al (number) (alphabet)]. The weighted
mean difference (MD) was calculated for numerical data, and
the odds ratio was calculated for dichotomous data, both with
95% CI. Statistical heterogeneity was assessed using the I2
index. Data were analyzed using a random effects model due
to clinical or methodological heterogeneity [10]. A statistical
significance was assumed if 95% CIs did not include the
value 1.0 for relative risk and 0 for MD.3. Results
A total of 287 papers on the xenon and other inhalation
anesthetics (1964-2013) were identified using the search
strategy. After carefully screening the titles and abstracts, 276
were excluded: 240 were not RCTs, 4 were animal
experiments, 28 were unrelated studies, 1 was a review article,
and 3 RCTs included unsuitable data presentations. Eleven
studies that included 661 patients were deemed eligible for
inclusion in this systematic review [2,3,11–19]. Three research
groupswere responsible for most of the studies included in this
Fig. 3 Forest plot of meta-analysis of trials comparing xenon anesthesia with other inhalation anesthesia on the time to recovery (open eyes)
and anesthetic parameters at the time points. (A) Time to open eyes. (B) BIS values at the time point eye opening. (C) OAA/S scores at the time
point eye opening. Studies with the same first author were numbered [author et al (number)]. Studies from the same first author with more than
one intervention group were numbered [author et al (number) (alphabet)]. Xenon, xenon anesthesia; others, other inhalation anesthesia.
69review. The analysis included 2 studies from the Morita group
[2,3], 2 studies from the Rossaint group [12,13], and 3 studies
from the Coburn group [15–17]. A flow chart that illustrates
how we located relevant studies is presented in Fig. 1. The
characteristics of the randomized trials are described in
Table 1. There was no important imbalance at baseline in
each study. The studies in this review included comparisons of
xenon versus other inhalation anesthetics. Inhalation anes-
thetics included methyl ethers, such as sevoflurane (6 studies)
[13–17,19], isoflurane (1 study) [18], and desflurane (1 study)
[12]. The remaining studies [2,3,11] included xenon alone or
comparisons to nitrous oxides in combination with either
sevoflurane or isoflurane.
3.1. Quality assessment
The methodological quality scores of the included studies are
summarized in Fig. 2. Six [3,12,14–17] of the 11 studies had an
adequate sequence generation for randomization.Only 1 study [3]
had allocation concealment, the remaining studies were unclear.With the exception of 2 studies [2,3] in which the blinding
protocol was unclear, participants, personnel, and outcome
assessors were blinded to randomized groups [11–19]. Six
[3,13,15–18] of the 11 studies were free of selective reporting.
3.2. Open eyes
Ten studies reported time to open eyes as mean and SD
(Fig. 3A) [2,3,11–13,15–19]. Patients in the xenon group
showed significantly faster recovery with respect to time to open
eyes than other inhalational anesthetics (MD, −4.18 minutes;
95% CI, −5.03 to −3.32 minutes; P b .00001; I2 = 96%).
Three studies recorded bispectral index (BIS) values at
the time of “eye opening” (Fig. 3B) [13,15,16]. There was
no difference in BIS values between the xenon group and
other inhalational anesthetics (MD, −10.55 minutes; 95%CI,
−23.27 to −2.18 minutes; P b .00001; I2 = 98%).
Two studies recorded the observer's assessment of
alertness/sedation scale (OAA/S) scores at the time of eye
opening (Fig. 3C) [13,16]. There was no difference between
Fig. 4 Forest plot of meta-analysis of trials comparing xenon anesthesia with other inhalation anesthesia on the time to recovery (reaction on
demand) and anesthetic parameters at the time points. (A) Time to reaction on demand. (B) BIS values at the time point reaction on demand.
(C) OAA/S scores at the time point reaction on demand. Studies with the same first author were numbered [author et al (number)]. Studies of
the same first author with more than one intervention group were numbered [author et al (number) (alphabet)]. Xenon, xenon anesthesia;
others, other inhalation anesthesia.
70 B. Hou et al.the xenon group and other inhalational anesthetics (MD, 0.02
minutes; 95% CI, −0.52 to 0.56 minutes; P = .12; I2 = 60%).
3.3. Reaction on demand
Seven studies reported time to reaction on demand
(Fig. 4A) [2,3,12,13,15–17]. Patients in the xenon group
showed significantly faster recovery with respect to time
to reaction on demand than groups treated with other
inhalational anesthetics (MD, −5.35 minutes; 95% CI, −6.59
to −4.11 minutes; P b .00001; I2 = 97%).
Three studies recorded BIS values at time to reaction on
demand (Fig. 4B) [13,15,16]. At those time points, BIS values
showed significantly lower levels in the xenon groups than
other inhalational anesthetics groups (MD, −7.49 minutes;
95% CI, −13.48 to −1.51 minutes; P b .00001; I2 = 96%).
Two studies recorded OAA/S scores at the time to
reaction on demand (Fig. 4C) [13,16]. There was no
difference between xenon groups and other inhalational
anesthetics (MD, −0.00 minutes; 95% CI, −0.0.5 to 0.05
minutes; P = .28; I2 = 13%).3.4. Extubation
Eleven studies reported time to extubation (Fig. 5A) [2,3,11–
19]. Patients in the xenon group showed significantly faster
recovery with respect to time to extubation than patients treated
with other inhalational anesthetics (MD, −4.49 minutes; 95%
CI, −5.4 to −3.58 minutes; P b .00001; I2 = 96%).
Three studies recorded BIS values at the time point
extubation (Fig. 5B) [13,15,16]. At the time points, BIS values
showed significantly lower levels in the xenon groups than
other inhalational anesthetics groups (MD, −7.95 minutes;
95% CI, −13.05 to −2.85 minutes; P b .00001; I2 = 97%).
Two studies recordedOAA/S scores at the time to extubation
(Fig. 5C) [13,16]. There was no difference between the xenon
groups and other inhalational anesthetics groups (MD, 0.20
minutes; 95% CI, 0.12 to 0.28 minutes; P = .79; I2 = 0%).
3.5. Orientation
Seven studies reported time to orientation (Fig. 6A)
[2,3,12,13,15–17]. Patients in the xenon group showed
Fig. 5 Forest plot of meta-analysis of trials comparing xenon anesthesia with other inhalation anesthesia on the time to recovery (extubation)
and anesthetic parameters at the time points. (A) Time to extubation. (B) BIS values at the time point extubation. (C) OAA/S scores at the time
point extubation. Studies with the same first author were numbered [author et al (number)]. Studies of the same first author with more than one
intervention group were numbered [author et al (number) (alphabet)]. Xenon, xenon anesthesia; others, other inhalation anesthesia.
71significantly faster recoverywith respect to time to orientation than
patients in other inhalational anesthetics groups (MD, −4.99
minutes; 95%CI,−6.45 to−3.52minutes;Pb .00001; I2 = 97%).
Three studies recorded BIS values at the time point
orientation (Fig. 6B) [13,15,16]. At the time points, BIS
values showed significantly lower levels in xenon groups than
other inhalational anesthetics groups (MD, −3.80 minutes;
95% CI, −4.39 to −3.22 minutes; P = .58; I2 = 0%).
Two studies recorded OAA/S scores at the time point
orientation (Fig. 6C) [13,16]. There was no difference
between the xenon group and other inhalational
anesthetics (MD, −9.65 minutes; 95% CI, −28.36 to 9.07
minutes; P b .00001; I2 = 100%).4. Discussion
Conventional volatile inhalational agents, in general, are
thought to produce anesthesia via interaction with receptortargets such as γ-aminobutyric acid receptors [20]. Xenon
exerts its anesthetic properties mainly by noncompetitively
inhibiting N-methyl-D-aspartate receptors [21,22], and 80%
xenon has been shown to reduce N-methyl-D-aspartate–
activated currents by approximately 60%. As an anesthetic
reagent, xenon possesses favorable properties such as
hemodynamic stability [12,23] and cardioprotective [24]
and neuroprotective effects [24,25]. Xenon was used as a
clinical anesthetic agent for more than 50 years until the late
1940s [26]. However, its clinical use has been limited
because of the high costs [27].
The most important pharmacokinetic property of xenon is
its blood-gas coefficient. In the late 1990s, Goto et al [2,3]
reported that recovery from xenon anesthesia was not only fast
but also smooth; no patients exhibited agitation or restlessness.
Our systematic review of previous studies has confirmed that
xenon has a more rapid recovery time than other inhalational
anesthetics. This effect is likely due to its blood-gas partition
coefficient, which is significantly lower than that of other
inhalational agents (xenon = 0.1154 vs nitrous oxide = 0.47,
Fig. 6 Forest plot of meta-analysis of trials comparing xenon anesthesia with other inhalation anesthesia on the time to recovery (orientation)
and anesthetic parameters at the time points. (A) Time to orientation. (B) BIS values at the time points orientation. (C) OAA/S scores at the
time point orientation. Studies with the same first author were numbered [author et al (number)]. Studies of the same first author with more than
one intervention group were numbered [author et al (number) (alphabet)]. Xenon, xenon anesthesia; others, other inhalation anesthesia.
72 B. Hou et al.sevoflurane = 0.65, isoflurane = 1.4, and desflurane = 0.42)
[1,28,29]. The results are consistent with the widely accepted
concept that the smaller the factor of blood-gas partition
coefficients is, the faster is the wake up time from anesthesia.
The studies included in this review did not report specifically
on the comparison of recovery parameters between xenon and
propofol anesthesia. Six studies [13–17,19] included in our
meta-analysis had a study arm with patients receiving xenon
and sevoflurane. All patients in the xenon group showed a
significantly faster recovery with respect to time to open eyes,
time to reaction on demand, time to extubation, and time to
orientation. Similar outcomes were observed in comparative
studies evaluating recovery parameters of xenon and isoflurane
[18] or desflurane [12]. In addition, recovery from xenon
anesthesia proved to be 2 or 3 times faster than recovery from
equi-minimum alveolar concentration (MAC) nitrous oxide–
isoflurane or nitrous oxide–sevoflurane anesthesia [2,3,11,30].
These studies suggested that anesthesia with xenon maybe a
good option for postanesthesia recovery periods.
One study [19] has investigated the effect of xenon on the
morbidly obese patients. Although obesity may increase therisk of recovery, it appears that there is no considerable
difference of recovery times with respect to normal-weight
patient trials. In the other 2 studies [11,18], investigators
used a recovery index (RI) to describe the recovery after
discontinuation of the anesthetic gas. The RI quotient uses
eyes opening time, extubation time, and Aldrete score
[11,18,31–33]. A difference in RI of 0.17 or higher was
classified as a clinically relevant advantage. The xenon
anesthesia group provided a distinctively faster recovery than
in the isoflurane-N2O group with a difference of 0.30.
Recently, monitoring depth of anesthesia raised concern
about recovery from general anesthesia. In our systematic
review, 3 measurements were used to monitor hypnotic
depth: BIS, auditory-evoked potential index, and A-line
autoregressive index [13,15,16]. The measurement of BIS is
the most widely used assessment of the actual state of
cerebral activity [34–36]. In this review, BIS values showed
significantly lower levels in the xenon group than in other
inhalation anesthesia groups at the time to open eyes,
reaction on demand, extubation, and orientation. Although
Goto et al [37] reported that the BIS values were lower than
7350 while awake, the validity of the BIS monitoring remains
controversial. This phenomenon may be due to an averaging
of data and technical delays caused by the fast emergence
from xenon anesthesia. Furthermore, display of BIS values
during awakening might lag behind the true electroenceph-
alogram processes. In our review, we found awakening at
BIS values greater than 50. It is indicated that when BIS
values were situated at the lower limit of the recommended
range of emergence, we could attempt to rouse patients from
anesthesia. In addition, the observer's determination of
OAA/S scores was assessed at the predefined time points
[38]. There was no difference between xenon and other
inhalation anesthesia due to small amounts of data. Only 2
studies [13,16] reported the measurement of auditory-evoked
potential index and A-line autoregressive index indepen-
dently in this review, and we did not analyze those data.
The heterogeneous nature of the data included in this
review was a limitation. Different types of anesthesia and
surgerical methods may confound clinical outcomes. The
comparative “other inhalational anesthesia” included a wide
variety of mixtures that may have also resulted in clinical
heterogeneity. In addition, there were no means to correct for
studies of differing quality. Furthermore, the age and weight
of patients, intraoperative opioids, isonipecotic acid con-
sumption, and reported outcomes resulting in the heteroge-
neity could alter study outcomes. The impact of
heterogeneity will have to be evaluated in future studies.
In conclusion, xenon anesthesia enables significantly faster
recovery from anesthesia than other inhalation anesthetic
agents. In spite of the high cost, xenon has characteristics that
could make its use ideal in certain patient populations. Large
and rigorous randomized trials in the future can focus on the
recovery parameters and other outcomes such as postoperative
cognitive dysfunction from xenon anesthesia.Acknowledgments
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